Family history of cardiovascular disease and influence on statin therapy persistence

European Journal of Clinical Pharmacology

Volumn 70, Issue 6, 2014, Pages 701-707

  Citarella, Anna ^a   Kieler, Helle ^a   Sundström, Anders ^a   Linder, Marie ^a   Wettermark, Björn ^a   Berglind, Ingegärd Anveden ^a   Andersen, Morten ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Persistence; Pharmacoepidemiology; Statin; Therapy discontinuation

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE; AGED; ARTICLE; BIRTH; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COHORT ANALYSIS; DISEASE SEVERITY; DRUG WITHDRAWAL; EDUCATION; FAMILY HISTORY; FEMALE; GENERAL PRACTITIONER; HEALTH CARE PERSONNEL; HEART INFARCTION; HOSPITALIZATION; HUMAN; INCOME; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; CARDIOVASCULAR DISEASES; EPIDEMIOLOGY; GENETICS; KAPLAN MEIER METHOD; MEDICATION COMPLIANCE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; SWEDEN; YOUNG ADULT;

ADULT; AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIER ESTIMATE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; SWEDEN; YOUNG ADULT;

EID: 84901666370     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1659-0     Document Type: Article

References (38)

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267-1278. doi:10.1016/S0140-6736(05)67394-1
2. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11(1):44-47. doi:10.1111/j.1524-4733.2007.00213.x
3. Corrao G, Conti V, Merlino L, Catapano AL, Mancia G (2010) Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy. Clin Ther 32(2):300-310. doi:10.1016/j.clinthera.2010.02.004
4. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA (2006) A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 333(7557):15. doi:10.1136/bmj.38875.675486.55
5. Rasmussen JN, Chong A, Alter DA (2007) Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 297(2):177-186. doi: 10.1001/jama.297.2.177
6. Penning-van Beest FJ, Termorshuizen F, Goettsch WG, Klungel OH, Kastelein JJ, Herings RM (2007) Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40 %: a cohort study. Eur Heart J 28(2):154-159. doi: 10.1093/eurheartj/ehl391
7. Colivicchi F, Bassi A, Santini M, Caltagirone C (2007) Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke J Cereb Circ 38(10):2652-2657. doi:10.1161/STROKEAHA.107.487017
8. Perreault S, Dragomir A, Blais L, Berard A, Lalonde L, White M (2008) Impact of adherence to statins on chronic heart failure in primary prevention. Br J Clin Pharmacol 66(5):706-716. doi:10.1111/j.1365-2125.2008.03269.x
9. Rasmussen JN, Gislason GH, Rasmussen S, Abildstrom SZ, Schramm TK, Kober L, Diderichsen F, Osler M, Torp-Pedersen C, Madsen M (2007) Use of statins and beta-blockers after acute myocardial infarction according to income and education. J Epidemiol Community Health 61(12):1091-1097. doi:10.1136/jech.2006. 055525
10. Jackevicius CA, Mamdani M, Tu JV (2002) Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288(4):462-467
11. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM (2004) Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 19(6):638-645. doi:10.1111/j.1525- 1497.2004.30516.x
12. Larsen J, Vaccheri A, Andersen M, Montanaro N, Bergman U (2000) Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy. Br J Clin Pharmacol 49(5):463-471
13. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353(5):487-497. doi:10.1056/NEJMra050100
14. Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM (2008) The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract 62(1):76-87. doi:10.1111/j.1742-1241.2007.01630.x
15. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X (2008) Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2, CD000011. doi:10.1002/14651858.CD000011.pub3
16. Zolnierek KB, Dimatteo MR (2009) Physician communication and patient adherence to treatment: ameta-analysis. Med Care 47(8):826-834. doi:10.1097/MLR.0b013e31819a5acc
17. Mann DM, Allegrante JP, Natarajan S, Halm EA, Charlson M (2007) Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther 21(4):311-316. doi:10.1007/s10557-007-6040-4
18. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A (2009) The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 24(11):659-667. doi:10.1007/s10654-009-9350-y
19. Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, Persson I, Sundstrom A, Westerholm B, Rosen M (2007) The new Swedish Prescribed Drug Register-opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16(7):726-735. doi:10.1002/pds.1294
20. World Health Organization (WHO) Oslo (2013). Guidelines for ATC classification and DDD assignment.WHO Collaborating Centre for Drug Statistics Methodology. www.whocc.no. Accessed 3 October 2013.
21. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M, Olausson PO (2011) External review and validation of the Swedish national inpatient register. BMC Public Health 11:450. doi:10.1186/1471-2458-11- 450
22. Ekbom A (2011) The Swedish Multi-generation Register. Methods Mol Biol 675:215-220. doi:10.1007/978-1-59745-423-0-10
23. Longitudinal integration database for health insurance and labour market studies (LISA by Swedish acronym). http://www.scb.se/Pages/List-257743.aspx. Accessed 3 October 2013.
24. Geers HC, Bouvy ML, Heerdink ER (2011) Estimates of statin discontinuation rates are influenced by exposure and outcome definitions. Ann Pharmacother 45(5):576-581. doi:10.1345/aph.1P607
25. Wallach Kildemoes H, Hendriksen C, Andersen M (2012) Drug utilization according to reason for prescribing: a pharmacoepidemiologic method based on an indication hierarchy. Pharmacoepidemiol Drug Saf 21(10):1027-1035. doi:10.1002/pds.2195
26. Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, Borghi C, Brignoli O, Caputi AP, Cricelli C, Mantovani LG (2009) Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 120(16):1598-1605. doi:10.1161/ CIRCULATIONAHA.108.830299
27. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J (2002) Long-term persistence in use of statin therapy in elderly patients. JAMA 288(4):455-461
28. Lemstra M, Blackburn D, Crawley A, Fung R (2012) Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol 28(5):574-580. doi:10.1016/j.cjca.2012.05.007
29. Perreault S, Blais L, Lamarre D, Dragomir A, Berbiche D, Lalonde L, Laurier C, St-Maurice F, Collin J (2005) Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 59(5):564-573. doi:10.1111/j.1365-2125.2005.02355.x
30. McGinnis B, Olson KL, Magid D, Bayliss E, Korner EJ, Brand DW, Steiner JF (2007) Factors related to adherence to statin therapy. Ann Pharmacother 41(11):1805-1811. doi:10.1345/aph.1K209
31. Chan DC, Shrank WH, Cutler D, Jan S, Fischer MA, Liu J, Avorn J, Solomon D, Brookhart MA, Choudhry NK (2010) Patient, physician, and payment predictors of statin adherence. Med Care 48(3):196-202. doi:10.1097/MLR.0b013e3181c132ad
32. Piette JD, Heisler M, Krein S, Kerr EA (2005) The role of patient-physician trust in moderating medication nonadherence due to cost pressures. Arch Intern Med 165(15):1749-1755. doi:10.1001/archinte.165.15.1749
33. Mann DM, Woodward M, Muntner P, Falzon L, Kronish I (2010) Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother 44(9):1410-1421. doi:10.1345/aph.1P150
34. Perreault S, Blais L, Dragomir A, Bouchard MH, Lalonde L, Laurier C, Collin J (2005) Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol 61(9):667-674. doi:10.1007/s00228-005-0980-z
35. Sanchez-Ramirez DC, Krasnik A, Kildemoes HW (2013) Do immigrants from Turkey, Pakistan and Ex-Yugoslavia with newly diagnosed type 2 diabetes initiate recommended statin therapy to the same extent as Danish-born residents? A nationwide register study. Eur J Clin Pharmacol 69(1):87-95. doi:10.1007/s00228-012-1306-6
36. Lauffenburger JC, Robinson JG, Oramasionwu C, Fang G (2013) Racial/Ethnic and Gender Gaps in the Use and Adherence of Evidence-Based Preventive Therapies among Elderly Medicare Part D Beneficiaries after Acute Myocardial Infarction. Circulation. doi: 10.1161/CIRCULATIONAHA.113.002658
37. West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A (1995) Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 142(10):1103-1112
38. Cohen JD, Brinton EA, Ito MK, Jacobson TA (2012) Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol 6(3):208-215. doi:10.1016/j.jacl.2012.03.003